RESEARCH & BUSINESS FOUNDATION SUNGKYUNKWAN UNIVERSITY
发明人:
CHO, Jae Youl,조재열,KIM, Mi Seon,김미선,BAEK, Kwangsoo,백광수,KIM, Yong,KIM, Eun Jee,김은지,PARK, Jae Gwang,박재광,YOO, Sul Gi,유슬기,KIM, Yu Lim,김유림,JEONG, Seong Gu,정성구,KIM, Yeo Jin,김여진
申请号：
KRKR2016/008401
公开号：
WO2017/023047A1
申请日:
2016.07.29
申请国别(地区):
WO
年份:
2017
代理人:
摘要：
The present invention relates to a composition for preventing or treating inflammatory disease or cancer, the composition containing aripiprazole as an active ingredient. The aripiprazole according to the present invention exhibits hardly any reduction in cell survival and is not cytotoxic in RAW264.7 cells, and, in RAW264.7 cells treated with peptidoglycan, exhibits an outstanding concentration-dependent NO production suppressing ability, prostaglandin E2(PGE2) production suppressing ability and cytokine (COX-2 and TNF-α) secretion suppressing ability, and had an outstanding stomach damage suppressing effect in an in vivo inflammatory model involving the induction of acute inflammation. Also, the aripiprazole according to the present invention has been confirmed to exhibit an outstanding cancer cell proliferation suppressing effect in C6, U251, LN-428 and MDA-MB-231 cells, and, in C6 cells, to increase the occurrence of blebbing and apoptotic bodies which are markers of apoptosis in a fashion dependent on the aripiprazole concentration, and to have an effect in promoting cancer cell apoptosis and in increasing the amount of active caspase. Hence, the present invention can be used as a medicinal product which is useful in preventing or treating inflammatory disease or cancer.La présente invention concerne une composition pour la prévention ou le traitement dune maladie inflammatoire ou du cancer, la composition contenant de laripiprazole en tant quingrédient actif. Laripiprazole, selon la présente invention, ne présente quasiment pas de réduction de la survie cellulaire et nest pas cytotoxique dans des cellules RAW264.7, et, dans des cellules RAW264.7 traitées par du peptidoglycane, présente de remarquables aptitude à la suppression de la production de NO dépendant de la concentration, aptitude à la suppression de la production de prostaglandine E2(PGE2) et aptitude à la suppression de la sécrétion de cytokine (COX-2 et TNF-α), et présente un excellent effet de supp
